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Abstract
Background: Several studies have examined reversibility of tardive syndromes (TS), primarily in psychotic patients who are maintained on dopamine receptor
blocking drugs. The results have varied widely. However, few have assessed remission rates after discontinuing the offending agents. This study evaluated
reversibility of TS in patients who permanently withdrew the causative agent(s). We also examined for any possible clinical predictors of reversibility.
Methods: A retrospective cohort of 108 TS patients was studied. Most of the patients were not psychotic; most patients were being treated either for a mood
disorder with atypical antipsychotics or for a gastrointestinal disturbance with metoclopramide. Patients were stratified on the basis of reversibility, and statistical
tests were used for subgroup comparisons of relevant clinical variables. Logistic regression was undertaken to identify clinical variables predictive of reversibility.
Results: Only 13% of the cohort experienced reversibility of the TS, 2% without medical intervention. When stratified by reversibility, there were no significant
differences in any study variables between subgroups. None of the study variables predicted reversibility in the logistic regression.
Discussion: Our study demonstrated a low remission rate for TS in a cohort of psychiatric and non-psychiatric patients seen in a movement disorder clinic after
the offending agents were completely withdrawn. Such a finding has significant prognostic implications. It is possible that limitations of the retrospective design may
have resulted in an underestimation. There is a clear need for prospective, multicenter, clinical trials in populations that can be safely withdrawn from dopamine
receptor blocking agents so that true remission rates can be measured.
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Introduction
Tardive syndromes (TSs) are iatrogenic movement disorders caused
by dopamine receptor blocking agents (DRBAs) and defined by at least
3 months’ exposure (1 month in patients .60 years of age).1 The first
cases were reported in the medical literature in 1957: three elderly
females developed lip-smacking dyskinetic movements 2–8 weeks after
initiating a chlorpromazine derivative.2,3 While the orofacial dyskine-
sia (‘‘classical tardive dyskinesia’’) originally described remains the
most common form of TS, other syndromes have been recognized
over the following decades, including dystonia, stereotypy, akathisia,
tremor, tics, myoclonus, and chorea—generalized, and truncal or
respiratory dyskinesias.4–6
With the approval of more than 10 atypical or second-generation
antipsychotic agents since the late 1980s, the prevalence rates for TSs
have been found in several trials for these drugs dating from 2004 to
2008 to be approximately 13% compared to 32% among subjects
treated with first-generation typical antipsychotics.7 This would suggest
that atypical antipsychotics may be associated with a lower risk of
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TSs.7 However, other more recent studies have suggested that there
may be no significant changes in the overall incidence of TS since the
introduction of second-generation antipsychotics.8,9 Considering that
there has been a more widespread use of atypical agents in non-
psychotic populations, likely related to their perceived safety in relation
to extrapyramidal symptoms, this could ultimately predict an even
greater occurrence of TSs.5 Furthermore, metoclopramide and other
antiemetics, also DRBAs that are used commonly for gastrointestinal
(GI) symptoms, represent important, often unaccounted for, causes of
TSs in non-psychiatric patients, with estimated TS frequencies being
as high as 30%.10–13
The prevalence rate of TS depends not only on exposure to DRBAs
but on reversibility of the disorder. The remission rate of TSs remains
unclear. TSs are generally thought to be reversible to some degree; the
rate of resolution is often quoted to be approximately 30% overall and
possibly lower in elderly people.14–16 While many studies examining
reversibility have been conducted in psychotic patients who continue
treatment with DRBAs, few studies have examined the remission rate
of TSs in patients in whom the offending agents are permanently
discontinued.17–21 Remission rates in these studies range from 2% to
33% with follow-up as long as 6.7 years. This is an important question
considering the apparent more widespread use of DRBAs.
Our study aims to evaluate the natural history of TSs in a
retrospective cohort of 108 mostly non-psychotic patients in whom the
offending agents were permanently removed. The primary outcome
variable was reversibility of the TS. Additional variables were collected
in order to evaluate for any potential clinical predictors of reversibility.
Methods
Approval through an expedited review process from the Emory
institutional review board was obtained for development of a patient
database and medical record review in the movement disorder clinic.
Patients seen between January 1, 2006, and December 31, 2009, with
a diagnosis of TSs were captured from this database and records were
obtained through our electronic medical record and reviewed.
Inclusion criteria were that patients met clinical diagnostic criteria
according to the ‘Diagnostic and statistical manual of mental disorders’
4th ed., text review (DSM-IV TR) of TSs and were diagnosed by a
movement disorder specialist; patients were exposed to a known
DRBA within 4 weeks prior to symptom onset and the causative agent
was specified in the record; the patients had at least one follow-up
(primarily by visit but rarely by a phone call [n52] that obtained
specific data on changes in their condition). Exclusions included those
patients who did not meet DSM-IV TR criteria, had dyskinesia that
may have been secondary to other causes or had an unknown etiology,
had incomplete information regarding the causative agent, and those
that did not return for any follow-up. In those with drug-induced
parkinsonism, diagnosis was established by history of exposure to block
dopamine agents, clinical evidence of at least two of four cardinal
features of parkinsonism (bradykinesia, rigidity, rest tremor, and
postural instability) and reversibility with removal of the inciting
agent.22
Once patients were identified, records were reviewed. All patients
had a standard new patient evaluation, including complete medical
history, past medical history including drug exposure, family history,
and complete neurological examination. Follow-up visits included
interim history, therapy review and response, and a neurological
examination. Demographic and clinical characteristics were collected
through record review, including age, gender, race, history of diabetes
mellitus, history of alcohol usage, the primary diagnosis for which the
DRBA was prescribed, the specific DRBA(s) prescribed, concomitant
extrapyramidal syndromes, the approximate dates the inciting drug
was started and stopped, the approximate date of onset of symptoms,
the type of TS (for example orofacial, generalized or respiratory
dyskinesia; orofacial, lingual, cervical, or generalized dystonia; or
akathisia), the date the TS resolved, and the date of last follow-up.
A scale was utilized to designate level of severity of the TS at the
initial and last evaluation as follows: none, mild, moderate, and severe.
Mild was described as those with mild or intermittent movements that
did not disturb the patient. Moderate was described as patients who
had minor difficulty with some activities of daily living (ADLs)
including eating or who found the movements bothersome or socially
embarrassing. Severe was described as those patients who had TS that
was disabling or giving trouble with some or all ADLs, such as the
disruption of eating to the point of causing weight loss or the loss of the
ability to walk or drive, or the presence of respiratory dyskinesia with
or without symptomatic shortness of breath.
Reversibility of TS was defined as complete resolution of the
movement disorder either spontaneously or with treatment, after
which resolution remained when treatment was discontinued.20 For
example, patients with tardive dystonia who had complete symptom
resolution only while on botulinum toxin treatment but returned after
it wore off were not considered as reversed. Those who had treatment,
which was then removed, and had no recurrence of symptoms, were
considered to be patients who had true resolution or reversibility of
TS. We also examined improvement of symptoms through use of the
severity scoring scale.
Statistical analysis
The cohort was stratified on the basis of TS reversibility, and
Student’s t-tests, chi-squared tests, and Fisher exact tests were used for
subgroup comparisons where appropriate. Logistic regression using
forward, backward, and stepwise selection strategies was undertaken in
order to identify clinical variables predictive of TD reversibility.
Results
We identified 126 patients who met diagnostic criteria for TS and
had documented DRBA exposure prior to onset. Sixteen of these
patients were lost to follow-up after one visit and two patients did not
have an offending agent specified. The remaining 108 patients were
the subjects of this analysis. In order to determine if the exclusion of
those lost to follow-up may have introduced any selection bias, a
separate analysis of baseline characteristics was done for the patients
lost to follow-up. This group was not significantly different from the
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108 patients included in the analysis with regard to any of the relevant
baseline characteristics (median age, gender distribution, primary
diagnosis, diabetes, alcohol abuse, offending agent, type of TS, severity
at baseline, mean exposure to offending drug, mean latency to onset).
For all subjects the DRBAs were stopped as the initial step in treating
the movement disorder and follow-up was done with their treating
movement disorder neurologist in our clinic, except for two patients
with a telephone follow-up.
Baseline characteristics are shown in Table 1. The mean age for the
cohort was 58.6¡17.7 years (range 10–87 years). Sixty-nine percent
were female. Most common ethnicities were 52.8% Caucasians and
12.0% African-American. The three most common primary diagnoses
resulting in the prescription of DRBA(s) were mood disorders (38.0%),
and GI illnesses (38.0%); only 6.48% had psychotic disorders. Drug-
induced parkinsonism was diagnosed in 25.9%. Diabetes was a
comorbid illness in 21.3% of the patients and alcohol abuse was
documented in 5.6%. Of the offending DRBAs, GI drugs were
prescribed in 41.7%, atypical antipsychotics in 36.1%, and first-
generation antipsychotics in 16.7%. Of the GI drugs, 86.7% were
exposed to metoclopramide. Tardive syndromes were further classified
by type of movement disorder: patients who had two or more different
types (referred to as mixed) were the most common (45.4%), followed
in descending order by orofacial, generalized or respiratory dyskinesias
(25.9%), orofacial or generalized dystonias (13%), and akathisia (5.
6%). The mean duration of exposure to the DRBA was 4.81¡6.26
years (range 0.02–28 years, median 2.07). The mean latency from drug
initiation to onset of the TS was 3.7¡5.6 years (range 0–29 years,
median 1.66 years). Average follow-up time for the study group was
3.1¡3.4 years (range 0–13.52 years, median 1.73 years).
The categories of treatments used for TSs included beta-blockers
(N535), benzodiazepines (N525), anticholinergics (N542), antiox-
idants (N514), amantadine (N523), vesicular monoamine transporter
inhibitors tetrabenazine or reserpine (N523), antiepileptics (N58),
dopamine agonists (N58), GABA agonists (N515), botulinum toxin
(N535), typical antipsychotics (N55), atypical antipsychotics (N525),
and deep brain stimulation (N57). Some patients were exposed to
more than one of these treatment categories. Ten patients had no
treatment exposure. Given the methodological limitations, we were
unable to assess the effectiveness of the specific TS treatments.
The primary endpoint of reversibility of TS in the 108 patients was
13% (n514). A second calculation was done to evaluate reversibility
among only those patients who had at least the mean follow-up (since
those seen earlier might still be in the process of resolution). Similarly,
13.9% of these patients resolved. Only 2.8% (n53) of the patients
resolved simply by withdrawing the offending agent. In the 14 patients
in whom TSs resolved, the average duration from onset of symptoms
to resolution was 4.3¡6.99 years (range 0.13–26.86 years, median
1.74 years). The average amount of time it took for TSs to resolve from
the end of drug exposure was 2.3¡2.3 years (range 0.10–6.34 years,
median 1.49 years). When stratified by reversibility, there were no
significant differences in any of the study variables (Table 2). None of
the study variables predicted reversibility in the logistic regression.
When baseline severity was compared to follow-up severity, a
general trend for improvement was seen (Figure 1). The number of
patients categorized with mild TSs at baseline examination increased
by over 1.6 times at the last follow-up after discontinuation of DRBA
regardless of the type of treatment used for TSs. The severe TS cohort
decreased by over 2.5 times at the last follow-up visit.
Discussion
We examined reversibility of TS in patients who were able to
permanently stop their inciting drug and found that a low percentage
of patients resolved, 13% overall and 2.8% simply with discontinuation
of the DRBA. The low percentage of TS reversibility in our cohort is
possibly secondary to a selection bias of the more difficult and
refractory cases of TS referred for treatment to a tertiary movement
disorder clinic. We also excluded 13% of our original cohort from
analysis due to loss of follow-up after one visit and these patients may
very well have had some form of improvement or even resolution after
the offending DRBA was removed perhaps resulting in the lack of need
for follow-up. The outcome of these considerations is possible
underestimation of the frequency of reversibility reported in this
study. Nevertheless, even if we included all of these patients as resolved
the frequency remains a quarter or less. There was also a tendency for
the severity of TS to improve to some extent over time without full
resolution. This may relate to either the treatments provided or just the
passage of time after stopping the offending agent. A prospective study
would be needed to confirm this finding. In our cohort of patients,
7.4% were exposed to only first generation typical antipsychotics and
36.1% were exposed to only second-generation DRBAs. It would
appear that even with atypical antipsychotics, the reversibility rates
remain low as only 20.5% of these cases resolved.
Previous studies that examined psychotic patients with TSs who had
their offending neuroleptic removed reported complete resolution
ranging as high as 92%.23–25 However, most of these studies were
conducted before the 1980s, which was the era of first generation
antipsychotics, involved small sample sizes and had follow-up periods
of 1 year or less.23–25 Our remission rates were more in the range of
those reported by Glazer et al.18 and Kang et al.20 Glazer followed 36
patients with a non-schizophrenic diagnosis and an additional 13
patients with schizophrenia or schizoaffective disorder who were
weaned off DRBAs for an average of 3.3 years. By the end of the study,
week 49, only one patient had ‘‘continued improvement’’ from the
baseline AIMS (Abnormal Involuntary Movement Scale) score (2%)
and 44 patients had relapses or were lost to follow-up.18 Kang et al.20
retrospectively evaluated 67 patients who primarily had tardive
dystonia, though many had mixed TS. Forty-two of them were able
to withdraw DRBAs permanently. These patients were followed for a
mean of 2.8 years (range 1 month to 5.2 years) and only five patients
had remission of their TS (12%).20 These studies suggest that designing
future prospective reversibility studies will require adequate follow-up
periods with continued visits even after TS has resolved. These study
populations were different from ours in that they consisted of primarily
psychiatric patients treated with first generation DRBAs while only
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Table 1. Baseline Characteristics of all 108 TS Patients
N5108 %











Mood disorder 41 38.0
GI illness 41 38.0




Tic disorders 6 5.56
Developmental d/o 2 1.85
Anxiety d/o 4 3.70
Personality d/o 1 0.930
Unknown 2 1.85
Diabetes 23 21.3
Alcohol abuse 6 5.56
Extrapyramidal symptoms
EPS (all categories) 35 32.4
Parkinsonism 28 25.9
EPS (not Parkinsonism) 7 6.48
Offending agent
GI DRBAs 45 41.7
Atypical antipsychotics 39 36.1
Mixed 15 13.9
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6.5% of ours had a psychotic disorder and our patients with psychiatric
disorders were treated most commonly with second-generation anti-
psychotics. In non-psychotic, non-psychiatric patients GI medications
such as metoclopramide were the offending agent in 41.7% of the cases
used alone or in combination with other DRBAs. This group of patients
did not show any statistically significant difference in reversibility when
compared to other offending agents implying that TS from GI
medications is as chronic and debilitating in a cohort of non-psychiatric
patients as TS from antipsychotics are in psychiatric populations.
Prognosticators for good outcomes, i.e., resolution or improvement,
have been examined previously and include younger age of onset,
psychiatric diagnosis, the course of the psychiatric disorder and
duration of therapy.5,26,27 Many of these predictors were reported
from studies in which exposure to DRBAs continued or were
restarted due to failure of withdrawal.18,28 In the 1990 study by
Glazer et al.,18 predictors of improvement or reversibility included
age less than 55 years, employment, and having a non-schizophrenic
diagnosis. Despite a small sample size and no statistical significance,
similar predictors of remission were reported by Kang including
young age of onset, shorter duration of exposure to DRBAs, and
faster withdrawal of DRBAs.20 We did not corroborate these findings
or find any other predictors of remission. This is possibly due in part
to the small sample size of patients with complete reversibility (n514)
and/or the retrospective nature of the study. However, there were a
few features with sizable percentage differences worth mentioning.
We did find that mood disorder made up a larger percentage of those
who resolved than those who did not (50% vs. 36.2%). This would
support prior findings noted above. Also, those who resolved were
younger 53.5 vs. 59.4 and in a larger percentage of those who
resolved the inciting agents were atypical antipsychotics (57%)
compared to those who did not (33%). On the other hand, our data
show that those who do not resolve are twice as likely to be treated for
Table 1. Continued
N5108 %







Orofacial/generalized dystonia 14 13.0
Akathisia 6 5.56
Lingual dystonia 5 4.63







Median duration of exposure to drug in years (range) 2.07 (0.02–29) (N565)
Median latency to onset of symptoms in years (range) 1.66 (0–29) (N568)
Abbreviations: d/o, disorder; DRBAs, Dopamine Receptor Blocking Agents; EPS, Extrapyramidal Symptoms; GI, Gastrointestinal; SD, Standard Deviation; SSRI, selective
serotonin reuptake inhibitors; TS, Tardive Syndromes.
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Table 2. Stratified Analysis: TS Resolved Group vs. TS Unresolved Group
TS Resolved TS Unresolved
p-Value
N514 (13.0%) N594 (87.0%)
Age (mean¡SD) 53.5¡20.0 59.4¡17.3 0.25
Range (18–87) Range (10–83)
Gender, n (%)
Female 10 (71.4) 65 (69.2) 0.99
Male 4 (28.6) 29 (30.9)
Ethnicity, n (%)
Caucasian 9 (64.3) 48 (51.1) 0.72
African-American 1 (7.14) 12 (12.8) 0.68
Hispanic 0 4 (4.26) 0.99
Asian 1 (7.14) 2 (2.13) 0.37
Unknown 3 (21.4) 28 (29.8)
Primary diagnosis, n (%)
Mood disorder 7 (50.0) 34 (36.2) 0.35
Psychotic disorder 1 (7.14) 6 (6.38) 0.99
GI illness 3 (21.4) 38 (40.4) 0.24
Neurodeg/stroke/
trauma
0 4 (4.25) 0.99
Other 3 (21.4) 10 (10.6) 0.37
Unknown 0 2 (2.13)
Diabetes, n (%) 3 (21.4) 20 (21.3) 0.99
Alcohol abuse, n (%) 0 6 (6.38) 0.99
Extrapyramidal
symptoms, n (%)
EPS present 3 (21.4) 32 (34.0) 0.54
Offending agent, n (%)
GI DRBAs 3 (21.4) 42 (44.7) 0.15
Atypical antipsychotics 8 (57.1) 31 (33.0) 0.13
Typical antipsychotics 0 8 (8.51) 0.59
SSRI 0 1 (1.06) 0.99
Mixed 3 (21.4) 12 (12.8) 0.41
Type of TS, n (%)
All dyskinesias 2 (14.3) 26 (27.7) 0.45
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Table 2. Continued
TS Resolved TS Unresolved
p-Value
N514 (13.0%) N594 (87.0%)
All dystonias 3 (21.4) 20 (21.3) 0.99
Other 3 (21.4) 5 (5.32) 0.07
Mixed 6 (42.9) 43 (45.7) 0.99
Baseline severity
Mild 3 (21.4) 38 (40.4) 0.24
Moderate 6 (42.9) 38 (40.4) 0.99
Severe 5 (35.7) 18 (19.2) 0.17
Latency to onset of symptoms (median, range) (1.3, 0–16.3) (1.8, 0–29) 0.99
Duration of drug exposure (median, range) (1.9, 0.04–16.4) (2.3, 0.02–29) 0.99
Duration of follow-up (median, range) (1.9, 0.34–6.1) (1.7, 0–13.5) 0.99
Duration from end of drug exposure to resolved TS
(median, range)
(1.5, 0.10–6.3) —
Total TS duration (median, range) (1.7, 0.13–26.9) —
Abbreviations: DRBAs, Dopamine Receptor Blocking Agents; EPS, Extrapyramidal Symptoms; GI, Gastrointestinal; SD, Standard Deviation; SSRI, selective serotonin
reuptake inhibitors; TS, Tardive Syndromes.
p-values calculated by two-sample t-test for continuous variables and Pearson’s x2 for categorical variables, two-sided p-values calculated at alpha50.05. p-value for
diabetes and alcohol abuse calculated by Fisher’s exact test, two-sided.
Figure 1. Trend in Tardive Syndrome Severity at Baseline and Last Follow-up.
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underlying GI illnesses with GI related dopamine blocking agents
such as metoclopramide.
Our study has limitations as alluded to previously. It is a
retrospective study, so there was not a standard measure for TSs such
as the AIMS, and duration of follow-up varied. A large prospective
trial will be needed to confirm our findings. As a movement disorder
specialty clinic, there is a likelihood of inclusion bias for the more
protracted cases. In addition, our population was mostly non-psychotic
so it may not be translatable to schizophrenia. Finally, the number of
resolved subjects was small and likely underpowered for examining for
prognosticators of good outcomes.
In conclusion, our study demonstrated a low remission rate for TSs in
psychiatric and non-psychiatric patients after DRBAs are withdrawn.
Despite the fact that our results could have been biased by the
retrospective nature of the study and the possible referral bias to the
movement disorder clinic, the results were similar to other such
examinations in psychiatric populations. The irreversibility of TSs has
serious prognostic implications and likely represents an important
reason for rising prevalence. The 2013 American Academy of
Neurology guideline on the treatment of TSs based on prior reports
was unable to provide conclusive guidelines on the benefits of long-term
DRBA withdrawal because of inadequate evidence and the lack of
longitudinal prospective studies.29 At best, with current treatment
options, our data suggest that there are small benefits with gradual
partial improvement and a few remissions. At worst it appears that TSs
are a permanent complication of DRBAs in most patients. Hence, by
the time TSs develop it is too late. There is a clear need for prospective,
multicenter, clinical trials in psychiatric and non-psychiatric TS
populations who can be safely withdrawn from DRBAs so that true
remission rates can be measured. For now, we can conclude that TSs are
an iatrogenic problem caused by exposure to DRBAs that are common
and increasing in frequency, embarrassing, disabling, and permanent in
a majority of those who develop them.5 This should be kept in mind
when considering prescribing this class of drugs. It also indicates that
some urgency is needed in the development of effective therapies.
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